Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Equity Ratio (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Equity Ratio readings, the most recent being 1.87 for Q1 2026.

  • On a quarterly basis, Equity Ratio fell 110.19% to 1.87 in Q1 2026 year-over-year; TTM through Mar 2026 was 1.87, a 110.19% decrease, with the full-year FY2025 number at 1.9, down 113.38% from a year prior.
  • Equity Ratio hit 1.87 in Q1 2026 for Atara Biotherapeutics, up from 1.9 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.6 in Q4 2023 to a low of 1.9 in Q4 2025.
  • Median Equity Ratio over the past 5 years was 0.59 (2024), compared with a mean of 0.43.
  • Biggest five-year swings in Equity Ratio: surged 78.21% in 2023 and later crashed 3225.27% in 2024.
  • Atara Biotherapeutics' Equity Ratio stood at 0.34 in 2022, then surged by 78.21% to 0.6 in 2023, then crashed by 248.72% to 0.89 in 2024, then tumbled by 113.38% to 1.9 in 2025, then rose by 1.94% to 1.87 in 2026.
  • The last three reported values for Equity Ratio were 1.87 (Q1 2026), 1.9 (Q4 2025), and 1.21 (Q3 2025) per Business Quant data.